Cipher Pharmaceuticals Inc.
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.
MISSISSAUGA, ON, Dec. 10, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that MOB-015, a product for the treatment of nail fungus, did not meet the primary endpoint in the North American Phase 3 study being conducted by Moberg. The results of the North American Phase 3 study communicated by Moberg today confirm the initial indications previously informed to the market by Moberg, and accordingly announced by Cipher, on September 13, 2024.
(All figures are presented in U.S. Dollars)
Successfully closed the acquisition of the U.S. based Natroba™ business on July 26, 2024Epuris sales volumes grew 29% compared to Q3 2023, continuing growth trajectory for the fifth consecutive quarterStrong product gross margin from the acquired Natroba products of 85%Added management depth with appointment of Dr. Hamed Ghanei, Chief Business OfficerMISSISSAUGA, ON, Nov. 7, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and nine months ended September 30, 2024.
MISSISSAUGA, ON, Nov. 4, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The Company will also hold a conference call on Friday, November 8, 2024 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Friday, November 8, 2024
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 02131#
Expires: November 15, 2024
WEBCAST:
https://app.webinar.net/BxoA3Pp3dnP
MISSISSAUGA, ON, Oct. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO").
Craig Mull, Interim Chief Executive Officer, commented on the appointment: "I am delighted to announce the addition of Dr. Ghanei to Cipher's executive team. Hamed's expertise in business development, including extensive experience with licensing deals and other M&A opportunities in the specialty pharmaceuticals and healthcare industries, make him an excellent fit for contributing to Cipher's next phase of substantial growth."
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.
TORONTO, Sept. 13, 2024 /CNW/ - Trading resumes in:
Company: Cipher Pharmaceuticals Inc.
TSX Symbol: CPH
All Issues: No
Resumption (ET): 10:12:56 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions
TORONTO, Sept. 13, 2024 /CNW/ - The following issues have been halted by CIRO:
Company: Cipher Pharmaceuticals Inc.
TSX Symbol: CPH
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 10:07:56 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
(All figures are presented in U.S. Dollars)
Adjusted EBITDA was $3.1 million in Q2 2024, consistent with Q2 2023Epuris sales volumes grew 13% compared to Q2 2023, continuing its growth trajectory for the fourth consecutive quarterStrong operating cash flows of $6.2 million in Q2 2024Management changes to take effect on August 10, 2024:CFO Bryan Jacobs to transition to President, focusing on the U.S. operationsVice President, Finance Ryan Mailling appointed as Chief Financial OfficerMISSISSAUGA, ON, Aug. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and six months ended June 30, 2024.
P R O D U C T S U G G E S T I O N S
